BGBurçak Tatlı Güneş

Burçak Tatlı Güneş

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Burçak Tatlı Güneş has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Laboratory-reassuring profiles in pediatric leukemia and lymphoma: a single-center cohort study

    by Mehtap Ertekin, Zühal Önder Siviş, Burcak Tatlı Güneş, Esin Özcan, Salih Gözmen

    Aims: Childhood leukemia and lymphoma may present with overlapping nonspecific symptoms, yet their initial laboratory profiles can differ substantially. Pediatric lymphoma, in particular, may present without cytopenia and with normal lactate dehydrogenase (LDH), potentially creating false reassurance.Methods: We conducted a retrospective single-center cohort study of 81 patients diagnosed with leukemia (n=49; B-ALL 28, T-ALL 7, AML 14) or lymphoma (n=32; NHL 17, Hodgkin lymphoma 15) between January 2024 and January 2026 at a tertiary pediatric hematology–oncology center. Clinical and laboratory findings were compared using Fisher’s exact and Mann–Whitney U tests. The primary analysis compared the prevalence of a laboratory-reassuring profile, defined as simultaneous absence of cytopenia and LDH ≤300 U/L. Results: The laboratory-reassuring profile was present in 16 of 32 lymphoma patients (50%) and in none of the 49 leukemia patients (0%; p

  • Open Access

    Clinical characteristics, risk factors, and short-term outcomes of pediatric thrombosis in hospitalized non-malignant patients: a single-center study

    by Mehtap Ertekin, Neryal Tahta, Zühal Önder Siviş, Burçak Tatlı Güneş, Esin Özcan, Salih Gözmen

    Aims: Thrombosis in pediatrics differs from that in adults and is mainly provoked. The main triggers include central venous catheterization, critical illness, infection, and immobilization. The factors associated with illness severity and short-term outcome in hospitalized children without cancer remain poorly defined. The aim of this study was to identify such factors and to describe short-term radiological outcomes.Methods: In this retrospective study, hospitalized non-cancer children (≤18 years old) with thrombosis were studied from October 2024 to July 2025. Data on demographics, risk factors, D-dimer levels, thrombophilia testing, treatment modalities, and radiographic responses at 1 and 3 months after diagnosis were collected.Results: Eighty-eight children (median age 2.0 years, IQR 0.0-11.2 years); 58.0% males. All thrombosis episodes occurred in the venous system, and 62.5% were related to the use of catheters. Immobility (48.9%) and sepsis (40.9%) emerged as the predominant risk factors. D-dimer median was 520 ng/ml (IQR 200-1136), with significantly higher levels observed among ICU/palliative care units than in other wards (p

  • Open Access

    Clinical Phenotypes and Glycopeptide Escalation Patterns in Pediatric Febrile Neutro-penia: Associations With Short-Term Outcomes and Acute Kidney Injury Risk

    by Neryal Tahta, Zuhal Onder Sivis, Mehtap Ertekin, Burcak Tatli Gunes, Silem Ozdem Alatas, Esin Ozcan, Salih Gözmen

    Febrile neutropenia (FN) in pediatric oncology is a clinically heterogeneous syndrome in which early antibiotic escalation decisions are frequently driven by nonspecific severity cues. We aimed to identify baseline clinical phenotypes of pediatric FN, to describe early glycopeptide escalation patterns across these phenotypes, and to examine their associations with short-term outcomes and acute kidney injury (AKI). We conducted a retrospective cohort study including 106 FN episodes in 82 pediatric oncology patients initially treated with piperacillin-tazobactam monotherapy. Baseline clinical and laboratory variables available within the first 6 hours of FN onset were used for unsupervised k-means clustering to derive latent clinical phenotypes. Early glycopeptide escalation was defined as initiation of vancomycin or teicoplanin within 48 hours. Associations with day-7 clinical outcomes and AKI were evaluated using cluster-robust multivariable regression and inverse probability of treatment weighting. Three distinct FN phenotypes were identified: a high-inflammatory/mucositis-dominant phenotype (39.6%), a hemodynamically severe phenotype (22.6%), and a lower-severity phenotype (37.7%). Early glycopeptide escalation occurred in 26.4% of episodes and was disproportionately concentrated in the high-inflammatory and hemodynamically severe phenotypes. AKI developed in 10.4% of FN episodes and clustered predominantly within escalation-prone phenotypes. After adjustment, early escalation was not associated with improved day-7 clinical success but was associated with a higher observed risk of AKI. Pediatric FN comprises distinct clinical phenotypes that differentially drive antibiotic escalation behavior and renal injury risk. A phenotype-informed approach may help optimize escalation decisions and potentially reduce preventable toxicity. However, given the observational design, these associations should be interpreted with caution.

  • Open Access

    Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study

    by Emine Zengin, Nazan Sarper, Arzu Yazal Erdem, Işık Odaman Al, Melike Sezgin Evim, Neşe Yaralı, Burcu Belen, Arzu Akçay, Ayşen Yıldırım, Tuba Hilkay Karapınar, et al.

    Objective: This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA). Materials and Methods: Retrospective data were collected from 13 Turkish pediatric hematology centers. The dose and duration of rtPA treatment, concomitant anticoagulant treatment, complete clot resolution (CCR), partial clot resolution (PCR), and bleeding complications were evaluated. Low-dose (LD) rtPA treatment was defined as 0.01-0.06 mg/kg/h and high-dose (HD) rtPA as 0.1-0.5 mg/kg/h. Results: Between 2005 and 2019, 55 thrombotic episodes of 54 pediatric patients with a median age of 5 years (range: 1 day to 17.75 years) were evaluated. These patients had intracardiac thrombosis (n=16), deep vein thrombosis (DVT) (n=15), non-stroke arterial thrombosis (n=14), pulmonary thromboembolism (PE) (n=6), and stroke (n=4). The duration from thrombus detection to rtPA initiation was a median of 12 h (range: 2-504 h) and it was significantly longer in cases of DVT and PE compared to stroke, non-stroke arterial thrombosis, and intracardiac thrombosis (p=0.024). In 63.6% of the episodes, heparin was initiated before rtPA treatment. LD and HD rtPA were administered in 22 and 33 of the episodes, respectively. Concomitant anticoagulation was used in 90% and 36% of the episodes with LD and HD rtPA, respectively (p=0.0001). Median total duration of LD and HD rtPA infusions was 30 h (range: 2-120 h) and 18 h (2-120 h), respectively (p=0.044). Non-fatal major and minor bleeding rates were 12.5% and 16.7% for LD and 3.2% and 25.8% for HD rtPA, respectively. At the end of the rtPA infusions, CCR and PCR were achieved in 32.7% and 49.0% of the episodes, respectively. The most successful site for thrombolysis was intracardiac thrombosis. HD versus LD rtPA administration was not correlated with CCR/PCR or bleeding (p>0.05). Conclusion: Systemic thrombolytic therapy may save lives and organs effectively if it is used at the right indications and the right times in children with high-risk thrombosis by experienced hematologists with close monitoring of recanalization and bleeding.


  • Evaluation of the achievement of hematologists to transfusion medicine education with self-assessment questionnaire in Turkey

    by Funda Tayfun Küpesi̇z, Neslihan Andic, Melike Sezgi̇n Evi̇m, İbrahim Eker, Fergun Aydi̇n, Gülen Tüysüz, Dilek Gürlek, Melek Isik, Yesim Oymak, Berna Atesagaoglu, et al.

    Background: Proper clinical use of blood and blood products requires competent theoretical and practical knowledge of transfusion medicine. The Curriculum Development and Standard Determination System Medical Specialization Board is prepared Hematology Specialist Education Core Curriculum in Turkey. In this study, we aimed to determine the access of hematologists to the learning objectives defined by curriculum for the transfusion medicine and the factors affecting it.Methods: Hematologists who have been members of Turkish Hematology Society since 2013 have been included in the study, The survey questions were prepared based on the curriculum for transfusion medicine. The study was applied to hematologists with "survey monkey" application. The questionnaire consisted of a competence self-assessment with Likert scale and theoretical multiple-choice knowledge questions. Results: Of the 213 hematologists, 54 (25%) were included in the study. Hematologists rated their competences in the clinical competence areas as 3,65 ± 0,73 (median 3,60) as "I know but not t a sufficient level". The participants 'perception of competence was "I know, but not at a sufficient level'" with an average of 3.31 ± 0.84 (median3.5) in the blood banking field, while the average in hemapheresis and transfusion medicine was 4.04 ± 0.63 (median 4) as "enough". In interventional procedures, hematologists stated that their vocational competences were 2,79± 0,92 (median 2,93) on average as "I have an idea- I know, but not enough". The correct answer to 13 theoretical questions was an average of 6,96 ± 1,89 (median 7). Hematologists performing blood rotation felt significantly more competent than the physicians who could not do the rotation in the blood bank, blood banking t(52) = -3.9, p < .001 , transfusion medicine and interventional competence t(52) = -2.2, p = .04 . Physicians who believed that they are sufficient in the blood banking area, were more confident in transfusion medicine r(54) = .67, p <.001 and managing interventional procedures r(54) = .85, p <.001. Conclusion: In this study, hematologists generally felt more competent in subjects such as transfusion and therapeutic apheresis, which they often think of as not having enough knowledge in the area of blood banking. Hematologists have been more confident in the field of transfusion medicine as their years of expertise increased, but they did not feel better equipped in the fields of blood banking and interventional competence. The current results suggested that hematologists who are expected to be the blood bank supervisors do not internalize the area of blood banking, are not strong in their competence, and do not want to work in this area unless they are required.In hematology education curriculum, positive revisions in education can be achieved by revising blood banking curriculum and learning objectives, standardizing blood center rotations with content and duration, and support from online distance education programs.